+3 years of our Journey & Key Milestones

Since 2023, our journey has been marked by significant growth and transformation. We embarked on a mission to address the grand challenges of current Pharmaceutical industry: high cost and risk, and slow development. We envisioned a "plug and play" world where different therapeutics or preventives could be rapidly generated using pre-approved and safe building blocks. Along the way, we encountered challenges that tested our resilience, yet each obstacle became an opportunity to learn and improve. Our commitment to collaboration has fostered a strong sense of community among our team, driving us to achieve remarkable milestones together. As we reflect on our progress, we remain focused on our vision for the future, eager to explore new horizons and continue our pursuit of excellence.

Our vision of a "plug and play" world to develop and construct new and efficacious therapeutics and preventives, and its impact on patients, the healthcare system, and the government.

Key milestones, 2023-2025

Commercial Development Fund

To generate proof of concept data supporting the development of "Plug and Play" nanocage assembly

Nov 2023

First Patent filed

We filed a patent application (WO2024110757A1) describing our "Plug and Play" nanocage assembly platform and its applications.

Oct 2023

Article published in the Multidisciplinary Journal Small

The research article describing our platform was published: A Versatile Virus‐Mimetic Engineering Approach for Concurrent Protein Nanocage Surface‐Functionalization and Cargo Encapsulation - Sheng - 2024 - Small - Wiley Online Library.

The article received news coverage, e.g., Vaccine Insights 2024; 3(4), 137–140

May 2024

MRC Gap Fund

We received a prestigious MRC Gap Fund to use our technology for developing novel broad-spectrum antiviral preventives and an approach to counter future viral pandemics.

Aug 2024

Joined King's Spinout Accelerator

The team joined King's Spinout Accelerator program to develop a commercialisation path and build its network of experts and investors.

Sept 2024

Second patent filed

We filed a second patent describing new enzymes as viral restriction factors for developing a synthetic innate immune system.

Oct 2024

POC Multifunctional broad-spectrum antivirals

We demonstrated the construction of highly efficacious antiviral nanocages that block influenza virus entry and infection in cell culture at nM concentrations.

Aug 2025

PROTEIX Biotech begins its journey

After months of building the technology and foundations of our commercialisation strategy, PROTEIX Biotech officially started its journey as a university-based start-up venture with support from an excellent advisory board (see our team).

Sept 2025

New cagebody concept described

We generated preliminary data showing a "Plug and Play" molecular assembly platform to create novel antibody-mimetic nanocages.

Oct 2025

Key milestones 2026

POC animal studies

In the first quarter we aim to generate proof-of-concept data showing safety of our platform in mice

Apr 2026

Starting new projects on developing antiviral vaccines

We aim to start a new project for developing novel vaccines with public health and veterinary use

May 2026

POC of the generation of new cancer chemoimmunotherapeutic agents

We aim to generate POC data showing the use of our platform technology in creating novel multipurpose and efficacious cancer chemoimmunotherapeutic agents.

Oct 2026